The platypus is one of the few mammals to produce venom. Males have a pair of spurs on their hind limbs which secrete venom that is only seasonally active to breeding season, supporting the theory that the use of venom is for competition of mates only, not protection. While the spur remains out of breeding season, the platypus's venom gland lacks secretion. While the after effects are described as excruciatingly painful, this venom is not lethal to humans, but it is lethal to smaller animals.
Spur and crural gland
The venom is produced in the crural glands of the male, which are kidney-shaped alveolar glands located in the upper thigh connected by a thin-walled duct to a calcaneus spur, or calcar, on each hind limb. Female platypuses, in common with echidnas, have rudimentary spur buds that do not develop (dropping off before the end of their first year) and lack functional crural glands. The spur is attached to a small bone that allows articulation; the spur can move at a right angle to the limb allowing a greater range of attack than a fixed spur would allow. The spur normally lies flat against the limb but is raised when required.
The crural gland produces a venom secretion containing at least nineteen different peptides, in addition to non-protein components. Those peptides which have been sequenced and identified fall into three categories: defensin-like peptides (OvDLPs), C-type natriuretic peptides (OvCNPs), and nerve growth factor (OvNGF). The different chemicals in the venom have a range of effects from lowering blood pressure to causing pain and increasing blood flow around the wound. Coagulating effects have been seen during experiments on laboratory animals, but this has not been observed consistently. Unlike snake venom, there appears to be no necrotic component in the Platypus' venom - although some muscle wastage has been observed in cases of envenomation in humans, it is likely that this is due to the inability to use the limb while the effects of the venom persist. It is unknown whether the pain caused is a result of the associated edema around the wound or whether the venom has a component that acts directly on the pain receptors.
Although platypus venom has a broadly similar range of effects and is known to consist of a similar selection of substances to reptilian venom, it appears to have a different function from those poisons produced by non-mammalian species: its effects are not life threatening but nevertheless powerful enough to cause serious impairment to the victim, which can lead to temporary paralysis. It is not used as a method of disabling nor killing prey, and although it acts as a defensive mechanism, only males produce venom. Since production rises during the breeding season it is theorized that it is used as an offensive weapon to assert dominance and control territory during this period. The genes involved in venom production are related to, though distinct from, those involved in reptilian venom production. This appears to be an example of convergent evolution.
Effect on humans
Although powerful enough to paralyze smaller animals, the venom is not lethal to humans. However, it produces excruciating pain that may be intense enough to incapacitate the victim. Swelling rapidly develops around the entry wound and gradually spreads outward. Information obtained from case studies shows that the pain develops into a long-lasting hyperalgesia that can persist for months but usually lasts from a few days to a few weeks. A clinical report from 1992 showed that the severe pain was persistent and did not respond to morphine.
In 1991, Keith Payne, a former member of the Australian Army and recipient of the Victoria Cross (Australia's highest award for valour) was struck on the hand by a platypus spur, while trying to rescue the stranded animal. He described the pain as worse than being struck by shrapnel. One month later he was still experiencing pain in that hand. In 2006, Payne reported discomfort and stiffness when carrying out some physical activities, such as using a hammer.
There have been no reported human fatalities. In his book "An Ancestor's Tale", evolutionary biologist Richard Dawkins suggests that the venom does indeed work directly on the brain's pain receptors. He goes on to suggest that its resistance to the effects of morphine is of great interest to researchers studying ways to mitigate the intense pain associated with some cancers.
- Whittington, Camilla, et al. ”Defensins and the convergent evolution of platypus and reptile venom genes.” Genome Research 18 (7 May 2008): 986-994. Web. 14 September 2014. <doi:10.1101/gr.7149808>
- J.R.Grant. "Fauna of Australia chap.16 vol.1b". Australian Biological Resources Study (ABRS). Retrieved 13 December 2006.
- Gerritsen, Vivienne Baillie (December 2002). "Platypus poison". Protein Spotlight (29). Retrieved 13 December 2006.
- "The venom of th platypus (Ornithorhynchus anatinus)". Retrieved 13 December 2006.
- G. M. de Plater, R. L. Martin, and P. J. Milburn (1995). "A =and biochemical investigation of the venom from the platypus (Ornithorhynchus anatinus)". Toxicon 33 (2): 157–169. doi:10.1016/0041-0101(94)00150-7. PMID 7597719.
- C.M. Whittington, A. T. Papenfuss, and P. Bansal, et al. (2008). "Defensins and the convergent evolution of platypus and reptile venom genes". Genome Research 18 (6): 986–984. doi:10.1101/gr.7149808. PMC 2413166. PMID 18463304.
- Warren, WC., Hillier, LDW., Graves, JAM., et al (2008). "Genome analysis of the platypus reveals unique signatures of evolution". Nature 453 (7192): 175–U1. doi:10.1038/nature06936. PMC 2803040. PMID 18464734.
- Torres, AM et al; Menz, I; Alewood, PF; Bansal, P; Lahnstein, J; Gallagher, CH; Kuchel, PW (2002). "D-Amino acid residue in the C-type natriuretic peptide from the venom of the mammal, Ornithorhynchus anatinus, the Australian platypus". FEBS Lett 524 (1–3): 172–6. doi:10.1016/S0014-5793(02)03050-8. PMID 12135762.
- G. M. de Plater, P. J. Milburn and R. L. Martin (2001-03-01). "Venom From the Platypus, Ornithorhynchus anatinus, Induces a Calcium-Dependent Current in Cultured Dorsal Root Ganglion Cells". Journal of Neurophysiology (American Physiological Society) 85 (3): 1340–1345. PMID 11248005.